Pipeline
By applying its specialized drug delivery expertise to established active ingredients, Orexo has successfully advanced multiple candidates from development to global commercialization.
The following product pipeline highlights Orexo's approved products based on the first-generation drug delivery technology - the sublingual.
| Launched products | Technology | Partnership | Preclinical | Clinical | Registration | Approved |
|---|
1995
Orexo is founded in Uppsala, Sweden, as a drug delivery company. Development begins based on first-generation drug delivery technology – the sublingual platform
2000
Diabact® UBT, for diagnosing Helicobacter pylori, receives first market approval and is commercialized through a partner
2008
Abstral®, for breakthrough cancer pain, launches in its first market via partnership
2009
Edluar®, for insomnia, achieves first market approval and is commercialized through partnership
2013
Zubsolv®, the third product based on the sublingual platform, is approved by the FDA for the treatment of opioid addiction. Orexo establishes a US subsidiary for commercialization
2016
Zubsolv in the US surpasses SEK 1 billion in gross sales
2017
Research into an overdose rescue medication started, leading to the development of next-generation drug delivery technology - AmorphOX®
2021
Pipeline expands with three clinical-phase programs and several preclinical projects all leveraging AmorphOX technology
2024
2025
Orexo divests all rights to Zubsolv in the US, unlocking resources to accelerate development programs
You are now leaving the Orexo AB (publ.) corporate website at orexo.com to visit the Orexo US, Inc. website at us.orexo.com.
